In these cancers, KRAS is responsible for approximately 45% of cases in CRC, 35% in NSCLC and 90% in PDAC with poor prognosis and resistance to standard-of-care chemotherapy, denoting a critically unmet medical need that requires novel therapies to target KRAS2. This evidence concerns the gene KRAS and non-small cell lung carcinoma.